The FDA has approved atezolizumab to treat urothelial carcinoma, the most common type of bladder cancer. Marketed as Tecentriq, the drug is the first PD-1/PD-L1 inhibitor, a form of immunotherapy, approved to treat bladder cancer.
Atezolizumab’s safety and efficacy were studied in a single-group trial with 310 patients who had locally advanced or metastatic urothelial carcinoma. About 15% of the patients treated had at least partial shrinkage of their tumors lasting from 2 to 14 months. Among patients who had high levels of PD-L1 protein expression, 26% experienced some tumor shrinkage compared with 9.5% who had low levels of PD-L1 expressed (http://1.usa.gov/206G1Nc).
Voelker R. New Bladder Cancer Drug. JAMA. 2016;316(1):24. doi:10.1001/jama.2016.8071